According to the most recent financial data from March 2025, the current EPS (TTM) is $2.68. Bristol Myers Squibb's EPS for 2024 came in at -$4.41, marking a decrease from $3.88 in 2023. For the quarterly period ending on Mar 31, 2025, BMY's EPS was $1.21.
Bristol Myers Squibb had an annual EPS of -$4.41, marking a decrease of 213.7% from $3.88 in 2023. The quarterly EPS for the period ending Mar 31, 2025, was $1.21, marking a 120.5% increase from the same quarter last year. BMY's TTM EPS stands at $2.68 as of March 2025. Bristol Myers Squibb's EPS for 2023 stood at $3.88, a 30.6% increase from 2022.
Bristol Myers Squibb has recorded an increase in EPS of 120.5% over the last 12 months (YoY, quarterly).
Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
---|---|---|---|---|
MRK Merck & Co Inc | 11.46 | 4,728.6% | 9.4% | 12% |
PFE Pfizer Inc | 16.8 | 273.7% | -28.7% | -13.2% |
JNJ Johnson & Johnson | 17.11 | -57.9% | -9.7% | 0.4% |
ABT Abbott Laboratories | 17.3 | 133.8% | 24.5% | 29.9% |
BMY Bristol Myers Squibb Co | 18.06 | -213.7% | N/A | N/A |
NVS Novartis AG | 18.33 | -17.2% | -17.9% | 2.9% |
AMGN Amgen Inc | 26.27 | -39.3% | -9.7% | -10.1% |
AZN Astrazeneca plc | 29.04 | 18.2% | 284.3% | 34.3% |
LLY ELI LILLY & Co | 62.39 | 102.1% | 24.1% | 5.7% |
ABBV AbbVie Inc | 80.44 | -12.1% | -28.2% | -14.7% |
All data is based on quarterly TTM periods, unless otherwise specified.